|
1
|
Takano M, Kikuchi Y, Yaegashi N, et al:
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin
for clear cell carcinoma of the ovary. Oncol Rep. 16:1301–1306.
2006.PubMed/NCBI
|
|
2
|
Tanaka H, Kihira T, Nomura Y and Ishihara
A: Salvage chemotherapy with a combination of irinotecan
hydrochloride and mitomycin C in elderly Japanese patients with
gynecological malignancies: a pilot study. J Infect Chemother.
12:220–223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iyer L, Das S, Janisch L, et al: UGT1A1*28
polymorphism as a determinant of irinotecan disposition and
toxicity. Pharmacogenomics J. 2:43–47. 2002.
|
|
4
|
Innocenti F, Undevia SD, Iyer L, et al:
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene
predict the risk of severe neutropenia of irinotecan. J Clin Oncol.
15:1382–1388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rouits E, Boisdron-Celle M, Dumont A,
Guérin O, Morel A and Gamelin E: Relevance of different UGT1A1
polymorphisms in irinotecan-induced toxicity: a molecular and
clinical study of 75 patients. Clin Cancer Res. 10:5151–5159. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Han JY, Lim HS, Shin ES, et al:
Comprehensive analysis of UGT1A polymorphisms predictive for
pharmacokinetics and treatment outcome in patients with
non-small-cell lung cancer treated with irinotecan and cisplatin. J
Clin Oncol. 24:2237–2244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Minami H, Sai K, Saeki M, et al:
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic
polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet
Genomics. 17:497–504. 2007.PubMed/NCBI
|
|
8
|
Jada SR, Lim R, Wong CI, et al: Role of
UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in
irinotecan-induced neutropenia in Asian cancer patients. Cancer
Sci. 98:1461–1467. 2007.
|
|
9
|
Hoskins JM, Goldberg RM, Qu P, Ibrahim JG
and McLeod HL: UGT1A1*28 genotype and irinotecan-induced
neutropenia: dose matters. J Natl Cancer Inst. 99:1290–1295.
2007.
|
|
10
|
Sai K, Saito Y, Sakamoto H, et al:
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan
toxicities in Japanese cancer patients. Cancer Lett. 261:165–171.
2008.
|
|
11
|
Han JY, Lim HS, Park YH, Lee SY and Lee
JS: Integrated pharmacogenetic prediction of irinotecan
pharmacokinetics and toxicity in patients with advanced non-small
cell lung cancer. Lung Cancer. 63:115–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Onoue M, Terada T, Kobayashi M, et al:
UGT1A1*6 polymorphism is most predictive of severe neutropenia
induced by irinotecan in Japanese cancer patients. Int J Clin
Oncol. 14:136–142. 2009.
|
|
13
|
Takano M, Kato M, Yoshikawa T, et al:
Clinical significance of UDP-glucuronosyltransferase 1A1*6 for
toxicities of combination chemotherapy with irinotecan and
cisplatin in gynecologic cancers: a prospective multi-institutional
study. Oncology. 76:315–321. 2009.
|
|
14
|
Takahara N, Nakai Y, Isayama H, et al:
Uridine diphosphate glucuronosyl transferase 1 family polypeptide
A1 gene (UGT1A1) polymorphisms are associated with toxicity and
efficacy in irinotecan monotherapy for refractory pancreatic
cancer. Cancer Chemother Pharmacol. 71:85–92. 2013. View Article : Google Scholar
|
|
15
|
Stewart CF, Panetta JC, O’Shaughnessy MA,
et al: UGT1A1 promoter genotype correlates with SN-38
pharmacokinetics, but not severe toxicity in patients receiving
low-dose irinotecan. J Clin Oncol. 25:2594–2600. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sugiyama T, Hirose T, Kusumoto S, et al:
The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in
patients with advanced lung cancer. Oncol Res. 18:337–342.
2010.
|
|
17
|
Guillemette C: Pharmacogenomics of human
UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3:136–158.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaniwa N, Kurose K, Jinno H, et al: Racial
variability in haplotype frequencies of UGT1A1 and glucuronidation
activity of a novel single nucleotide polymorphism 686C> T
(P229L) found in an African-American. Drug Metab Dispos.
33:458–465. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kurose K, Sugiyama E and Saito Y:
Population differences in major functional polymorphisms of
pharmacokinetics/pharmacodynamics-related genes in Eastern Asians
and Europeans: implications in the clinical trials for novel drug
development. Drug Metab Pharmacokinet. 27:9–54. 2012. View Article : Google Scholar
|
|
20
|
Imai Y, Nakane M, Kage K, et al: C421A
polymorphism in the human breast cancer resistance protein gene is
associated with low expression of Q141K protein and low-level drug
resistance. Mol Cancer Ther. 1:611–616. 2002.PubMed/NCBI
|
|
21
|
Han JY, Lim HS, Yoo YK, et al:
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with
irinotecan-pharmacokinetics and clinical outcome in patients with
advanced non-small cell lung cancer. Cancer. 110:138–147. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
National Cancer Institute. Common
Terminology Criteria for Adverse Events v 3.0 (CTCAE). Cancer
Therapy Evaluation Program. 2006.
|
|
23
|
Moriya H, Saito K, Helsby N, et al: The
association between heterozygosity for UGT1A1*6, UGT1A1*28, and
variation in the serum total-bilirubin level in healthy young
Japanese adults. Genet Test Mol Biomarkers. 17:464–469. 2013.
|
|
24
|
Gao J, Zhou J, Li Y, Lu M, Jia R and Shen
L: UGT1A1*6/*28 polymorphisms could predict irinotecan-induced
severe neutropenia not diarrhea in Chinese colorectal cancer
patients. Med Oncol. 30:6042013.
|
|
25
|
Comella P, Farris A, Lorusso V, et al:
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus
every other week may be a suitable therapeutic option also for
elderly patients with metastatic colorectal carcinoma. Br J Cancer.
89:992–996. 2003. View Article : Google Scholar
|
|
26
|
Chau I, Norman AR, Cunningham D, et al:
Elderly patients with fluoropyrimidine and thymidylate synthase
inhibitor-resistant advanced colorectal cancer derive similar
benefit without excessive toxicity when treated with irinotecan
monotherapy. Br J Cancer. 91:1453–1458. 2004. View Article : Google Scholar
|
|
27
|
Souglakos J, Pallis A, Kakolyris S, et al:
Combination of irinotecan (CPT-11) plus 5-fluorouracil and
leucovorin (FOLFIRI regimen) as first line treatment for elderly
patients with metastatic colorectal cancer: a phase II trial.
Oncology. 69:384–390. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rougier P, Bugat R, Douillard JY, et al:
Phase II study of irinotecan in the treatment of advanced
colorectal cancer in chemotherapy-naive patients and patients
pretreated with fluorouracil-based chemotherapy. J Clin Oncol.
15:251–260. 1997.PubMed/NCBI
|
|
29
|
Okuyama Y, Hazama S, Nozawa H, Kobayashi
M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K,
Sakamoto J and Mishima H: Prospective phase II study of FOLFIRI for
mCRC in Japan, including the analysis of UGT1A1 *28/*6
polymorphisms. Jpn J Clin Oncol. 41:477–482. 2011.
|
|
30
|
Sunakawa Y, Ichikawa W, Fujita K, et al:
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy
and toxicity of FOLFIRI in Japanese patients with advanced
colorectal cancer. Cancer Chemother Pharmacol. 68:279–284.
2011.
|
|
31
|
Cha PC, Mushiroda T, Zembutsu H, et al:
Single nucleotide polymorphism in ABCG2 is associated with
irinotecan-induced severe myelosuppression. J Hum Genet.
54:572–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sai K, Saito Y, Maekawa K, et al: Additive
effects of drug transporter genetic polymorphisms on irinotecan
pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Cancer Chemother Pharmacol. 66:95–105. 2010. View Article : Google Scholar
|
|
33
|
Cecchin E, Innocenti F, D’Andrea M, et al:
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants
and their haplotypes on the outcome of metastatic colorectal cancer
patients treated with fluorouracil, leucovorin, and irinotecan. J
Clin Oncol. 27:2457–2465. 2009. View Article : Google Scholar
|
|
34
|
Lévesque E, Bélanger AS, Harvey M, et al:
Refining the UGT1A haplotype associated with irinotecan-induced
hematological toxicity in metastatic colorectal cancer patients
treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol
Exp Ther. 345:95–101. 2013.
|
|
35
|
Glimelius B, Garmo H, Berglund A, et al:
Prediction of irinotecan and 5-fluorouracil toxicity and response
in patients with advanced colorectal cancer. Pharmacogenomics J.
11:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van der Bol JM, Mathijssen RH, Loos WJ, et
al: Cigarette smoking and irinotecan treatment: pharmacokinetic
interaction and effects on neutropenia. J Clin Oncol. 25:2719–2726.
2007.PubMed/NCBI
|
